Related Experiment Video
Updated: Feb 10, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
Eszter Molnár1, Dominika Rittler1, Marcell Baranyi1
12nd Department of Pathology, Semmelweis University, Budapest, 1091, Hungary.
Background:
Currently, there are no available targeted therapy options for non-V600 BRAF mutated tumors. The aim of this study was to investigate the effects of RAF and MEK concurrent inhibition on tumor growth, migration, signaling and apoptosis induction in preclinical models of non-V600 BRAF mutant tumor cell lines.
Methods:
Six BRAF mutated human tumor cell lines CRL5885 (G466 V), WM3629 (D594G), WM3670 (G469E), MDAMB231 (G464 V), CRL5922 (L597 V) and A375 (V600E as control) were investigated. Pan-RAF inhibitor (sorafenib or AZ628) and MEK inhibitor (selumetinib) or their combination were used in in vitro viability, video microscopy, immunoblot, cell cycle and TUNEL assays. The in vivo effects of the drugs were assessed in an orthotopic NSG mouse breast cancer model.
Results:
All cell lines showed a significant growth inhibition with synergism in the sorafenib/AZ628 and selumetinib combination. Combination treatment resulted in higher Erk1/2 inhibition and in increased induction of apoptosis when compared to single agent treatments. However, single selumetinib treatment could cause adverse therapeutic effects, like increased cell migration in certain cells, selumetinib and sorafenib combination treatment lowered migratory capacity in all the cell lines. Importantly, combination resulted in significantly increased tumor growth inhibition in orthotropic xenografts of MDAMB231 cells when compared to sorafenib - but not to selumetinib - treatment.
Conclusions:
Our data suggests that combined blocking of RAF and MEK may achieve increased therapeutic response in non-V600 BRAF mutant tumors.
Insights
Targeted therapy for non-V600 BRAF mutant tumors is lacking. Combined RAF and MEK inhibition shows promise, reducing tumor growth and increasing apoptosis in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Targeted therapy options for non-V600 BRAF mutated tumors are currently unavailable.
- RAF and MEK signaling pathways are crucial in various cancer types.
Purpose of the Study:
- To investigate the efficacy of concurrent RAF and MEK inhibition.
- To evaluate tumor growth, migration, signaling, and apoptosis in non-V600 BRAF mutant preclinical models.
Main Methods:
- Utilized six non-V600 BRAF mutated human tumor cell lines and one V600E control.
- Employed pan-RAF inhibitors (sorafenib/AZ628) and a MEK inhibitor (selumetinib) in combination for in vitro and in vivo studies.
- Assessed drug effects using viability, microscopy, immunoblot, cell cycle, TUNEL assays, and an orthotopic mouse model.
Main Results:
- Combination therapy demonstrated synergistic tumor growth inhibition and increased apoptosis induction compared to single agents.
- Concurrent inhibition led to enhanced Erk1/2 pathway suppression.
- Combination treatment reduced cell migration, unlike single MEK inhibition which sometimes increased it.
Conclusions:
- Combined RAF and MEK inhibition presents a potential therapeutic strategy for non-V600 BRAF mutant tumors.
- This approach may offer improved treatment responses where targeted therapies are currently lacking.
Related Concept Videos
Feedback Inhibition
Vertical Curve: Problem Solving
Introduction to Vertical Curves
Elevation of Intermediate Points on Vertical Curves
Sight Distance in a Vertical Curve
Enzyme Inhibition

